Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
Republicans defend drug company in spotlight over HIV medication prices

Republican members of Congress defended Gilead, the leading manufacturer of HIV drugs in the U.S., during a testy hearing Thursday as Democrats blasted the company over the prices of its products.

Published
17 May 2019
From
The Hill
Trump Administration Caves To Pharma On Medicare Part D 'Protected Classes' Reform

The Trump administration has shelved a proposal that would have stymied egregious price hikes in the Medicare prescription drug program. It’s a major win for the drug industry, and a defeat for Trump’s goal of reducing drug prices.

Published
17 May 2019
From
Forbes
One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

One in 3 people in a 286-person French HIV group took illicit drugs that sometimes posed a risk of severe interactions with antiretrovirals. Many potential interactions involved the boosting agents ritonavir or cobicistat.

Published
17 May 2019
From
NATAP
Being black and gay: how intersectional stigma impacts on the uptake of PrEP

Qualitative research published in the July issue of Social Science & Medicine by Dr Katherine Quinn and colleagues at the Center for AIDS Intervention Research highlights how

Published
17 May 2019
By
Krishen Samuel
Vienna Life Ball to raise money for HIV/Aids charities to end

Organisers say it is hard to find sponsors for the event because of progress in tackling the virus.

Published
17 May 2019
From
BBC News
A Leading HIV Drug Is Way Overpriced in the U.S.

A House hearing over the price of Truvada shows a particularly glaring example of a rampant industry practice.

Published
17 May 2019
From
Bloomberg
Alexandria Ocasio-Cortez Tells Gilead CEO That ‘People Are Dying’ Because His Company Charges Nearly $2,000 For Drug That Sells For $8 In Australia

"I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we led and developed all the patents to create PrEP [the commonly known name for Truvada] and then that patent has been privatized, despite the fact that the patent is owned by the public, who refused to enforce it," the representative said. “There’s no reason this should be $2,000 a month. People are dying because of it,” she added.

Published
17 May 2019
From
Newsweek
CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA

After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA. Trial will include 10 weeks of induction therapy to identify which patients are likely to respond and which patients can safely return to their original HAART regimen.

Published
17 May 2019
From
CytoDyn press release
New Zealand: The tide turns on HIV

The goal to virtually eliminate HIV transmission in NZ by 2025 suddenly looks attainable. Dr Peter Saxon explains why.

Published
17 May 2019
From
Newsroom
Rapid rehousing support for homeless people living with HIV improves housing and HIV outcomes

Homeless people with HIV who are provided with rapid rehousing and intensive, tailored case management are placed in stable housing more quickly and are twice as likely to

Published
17 May 2019
By
Michael Carter
← First12345...2611Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.